A5314: Effect of LDMTX on Inflammation in HIV-infected Individuals

Study Location:

Baltimore

Topic:

HIVCardiovascular Disease and HIV

Clinicaltrials.gov Link:

https://clinicaltrials.gov/ct2/show/NCT01949116?term=a5314&rank=2

IRB#:

NA_00088694

Coordinator:

Ilene Wiggins, RN

Enrollment:

Closed

Trial Period:

Completed

A5314 is a phase II randomized, double-blind, placebo-controlled 36-week trial that will examine the safety and efficacy of LDMTX on endothelial function and inflammation in virologically suppressed HIV-infected participants.

HIV-infected men and women ≥40 years old, who have been virologically suppressed on continuous antiretroviral therapy for at least 24 weeks; who have a CD4+ T-cell count ≥400 cells/mm3; and who have documented CVD or who are at increased CVD risk.

410-955-2898

Categories

Location
Topic

Clinical Trials

A5290: Randomized, Phase 2b Study of a Double-Dose...

Rifampin (RIF), the cornerstone of TB treatment, has very problematic drug-drug interactions with PIs. The use of relatively...

Read More

A5350: Effects of Visbiome Extra Strength on Gut Microbiome...

Many factors contribute to the development of aging-related conditions, including gastrointestinal (GI) diseases, such as...

Read More

A5128: Consent for Use of Stored Patient Specimens for...

The purpose of this study is to obtain informed consent to use stored human biological materials (HBM) (e.g., blood and other...

Read More

P1073: Study of Immune Reconstitution Inflammatory Syndrome...

P1073 is a case controlled prospective, clinical, observational and pathogenesis study of HIV-infected infants and children...

Read More

NWCS 408: Examining Longitudinal Cytokine Profiles in HIV-TB...

Using existing data from A5274 and data obtained from retrospectively testing available biospecimens, we propose the following...

Read More